Qian J, Nie W, Lu J, et al. - Among Asian and white patients receiving immunotherapy for nonsmall cell lung cancer (NSCLC), researchers compared characteristics and prognoses to define any possible disparities in these aspects between these populations. An analysis of 390 patients who took atezolizumab as part of the POPLAR or OAK trial was done. They found Asian vs white patients had a longer overall survival (OS). An independent prognostic factor for OS was race, combined with performance status, histology, baseline sum of the longest tumor diameters (BLSLD) and number of metastatic sites. Features such as smoking history, BLSLD, epidermal growth factor receptor mutation frequency, programmed death-ligand 1 expression and blood-based tumor-mutation burden were different between the two groups. The observed superior outcome induced by atezolizumab in Asian patients with NSCLC may be explained by the identified distinct clinicopathological characteristics and mutation profiles in Asian and white patients.